SCHEMBL7101151

SCHEMBL7101151

c1ccc2cc3c(cc2c1)ncc1ncsc13

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PI4KA P42356 1/20 0.42
PI4K2B Q8TCG2 1/20 0.42
PI4K2A Q9BTU6 1/20 0.42
PI4KB Q9UBF8 1/20 0.42
ALDH1A1 P00352 3/20 0.37
HSD17B10 Q99714 1/20 0.37
NQO2 P16083 1/20 0.36
KDM4E B2RXH2 3/20 0.36
GPR3 P46089 1/20 0.36
RPS6KB2 Q9UBS0 1/20 0.35
CYP1A2 P05177 2/20 0.34
MAPT P10636 3/20 0.34
ESR1 P03372 2/20 0.34
ESR2 Q92731 2/20 0.34
MEN1 O00255 2/20 0.33
GLA P06280 2/20 0.33
GAA P10253 2/20 0.33
RAB9A P51151 2/20 0.33
KMT2A Q03164 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2401192 0.78 ALDH1A1 (0.47) PI4KAPI4K2BPI4K2API4KBALDH1A1
SCHEMBL30402017 0.78 ALDH1A1 (0.47) PI4KAPI4K2BPI4K2API4KBALDH1A1
SCHEMBL29966574 0.77 ALDH1A1 (0.38) PI4KAPI4K2BPI4K2API4KBALDH1A1
SCHEMBL6536967 0.77 ALDH1A1 (0.38) PI4KAPI4K2BPI4K2API4KBALDH1A1
Ammonia Solution, Strong SCHEMBL6783413 0.77 ALDH1A1 (0.45) PI4KAPI4K2BPI4K2API4KBALDH1A1
Hydrochloric Acid SCHEMBL10466114 0.77 ALDH1A1 (0.45) PI4KAPI4K2BPI4K2API4KBALDH1A1
SCHEMBL10465960 0.72 NR4A2 (0.42) ALDH1A1HSD17B10CYP1A2MAPTMEN1
SCHEMBL29871387 0.71 CYP3A4 (0.47) ALDH1A1HSD17B10KDM4EGPR3MAPT
SCHEMBL2852558 0.71 CYP3A4 (0.47) ALDH1A1HSD17B10KDM4EGPR3MAPT
SCHEMBL1156175 0.70 ALDH1A1 (0.56) PI4KAPI4K2BPI4K2API4KBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1325009-A2 AMINO-SUBSTITUTED TETRACYCLIC COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME Bristol-Myers Squibb Company (US) 2003-07-09 EP disclosed
US-20030022898-A1 Methods of treating inflammatory and immune diseases using inhibitors of IkappaB kinase (IKK) BRISTOL-MYERS SQUIBB COMPANY 2003-01-30 US disclosed
WO-2002028860-A2 AMINO-SUBSTITUTED TETRACYCLIC COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME BRISTOL-MYERS SQUIBB COMPANY (US) 2002-04-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030022898-A1 Methods of treating inflammatory and immune diseases using inhibitors of IkappaB kinase (IKK) NFKBIA, IKBKG, IKBKB PI4KA 301/4885PI4K2B 476/4885PI4K2A 483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.